on Onco-Innovations Limited (CVE:ONCO)
Onco-Innovations and Kuano Collaborate on PNKP Inhibitor Development
On November 18, 2025, Onco-Innovations Limited announced a pilot project partnering with Kuano Ltd. The collaboration aims to accelerate the development of PNKP Inhibitor Technology, also known as A83B4C63. This initiative utilizes advanced molecular modeling and AI-driven compound design to refine compound architecture and expand the library of optimized analogs, thus enhancing the potential of developing selective and potent inhibitors.
Kuano will employ its quantum-ready analytics platform to provide detailed insights into PNKP inhibition. The collaboration is expected to guide structure optimization, generating potential candidates for Onco's next-generation therapeutics. The pilot project will run through Q4 2025, focusing on enhancing understanding through quantum-level analytics.
This strategic move is part of Onco-Innovations' goal to lead in next-generation oncology.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Onco-Innovations Limited news